[et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.27.6″ _module_preset=”93af678d-99a3-440b-b0d9-3a4356a67f33″ background_color=”#1A1B4D” use_background_color_gradient=”off” background_image=”https:\/\/alzorabio.com\/wp-content\/uploads\/2025\/11\/non-profit-03.jpg” custom_margin=”||-1px||false|false” locked=”off” collapsed=”on” global_colors_info=”{%22gcid-1f1bf5fb-a99d-4acc-8d9e-ddac074c158c%22:%91%22background_color_gradient_stops%22,%22background_color_gradient_stops%22,%22background_color_gradient_stops%22%93,%22gcid-4c79ba3d-a281-4fb6-9b14-02f9a4c793f2%22:%91%22background_color_gradient_stops%22,%22background_color_gradient_stops%22,%22background_color_gradient_stops%22%93,%22gcid-688c464a-d6f2-4296-b592-395352c71c79%22:%91%22background_color_gradient_stops%22,%22background_color_gradient_stops%22,%22background_color_gradient_stops%22%93,%22gcid-d119accd-44d7-4f2f-b9d7-599c8463324b%22:%91%22background_color_gradient_stops%22,%22background_color_gradient_stops%22,%22background_color_gradient_stops%22%93,%22gcid-2352d280-fe84-43b1-a71e-f400c35a526a%22:%91%22background_color_gradient_stops%22%93,%22gcid-9e22d70d-67ee-4430-bed3-4bc105d4ef1e%22:%91%22background_color_gradient_stops%22%93}”][et_pb_row _builder_version=”4.27.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Advancing Safer Alzheimer\u2019s Antibody Therapies” _builder_version=”4.27.6″ _module_preset=”2129416d-05c9-4b8d-a7b3-cd707c19bf47″ title_font=”–et_global_heading_font||||||||” title_text_align=”center” title_text_color=”#D4B4F9″ title_font_size=”48px” custom_margin=”||10px||false|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”e7a564bb-6a65-4b14-9846-5d6b684cf4df” text_font=”–et_global_body_font||||||||” text_text_color=”#FFFFFF” text_orientation=”center” global_colors_info=”{}”]<\/p>\n
Alzora Bio is developing next-generation immunotherapy designed to maintain efficacy while reducing ARIA risk, monitoring burden, and barriers to clinical adoption.<\/p>\n
[\/et_pb_text][et_pb_button button_text=”Explore Our Approach” button_alignment=”center” _builder_version=”4.27.6″ _module_preset=”480fe682-50a9-4927-8d88-261e97d9c305″ button_bg_color=”#D4B4F9″ hover_enabled=”0″ locked=”off” global_colors_info=”{}” button_url=”#learn” sticky_enabled=”0″][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”About” _builder_version=”4.27.6″ _module_preset=”afd460cc-f6d0-4b9d-b4be-304acb0693ae” background_color=”#FFFFFF” custom_margin=”||||false” custom_padding=”||||true|false” locked=”off” collapsed=”on” global_colors_info=”{%22gcid-1f1bf5fb-a99d-4acc-8d9e-ddac074c158c%22:%91%22background_color_gradient_stops%22%93,%22gcid-a78660e1-cfc7-4771-a566-6834d6a7f06a%22:%91%22background_color_gradient_stops%22%93,%22gcid-24b0db87-dafa-47d9-995f-b90181e18c52%22:%91%22background_color_gradient_stops%22%93}”][et_pb_row _builder_version=”4.25.2″ _module_preset=”default” max_width=”900px” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”About Us” _builder_version=”4.27.6″ _module_preset=”c8a67fc9-4c23-41fb-9fb6-d0146d1eb229″ title_font=”–et_global_heading_font|700||on|||||” title_text_align=”center” title_text_color=”#D4B4F9″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”d4bf98c7-0ca4-43df-b91e-5ed3c2635018″ text_font=”–et_global_body_font||||||||” text_text_color=”#1A1B4D” text_font_size=”24px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n
Alzora Bio is a research group based at the University of Southampton focused on developing next-generation antibody therapies for Alzheimer\u2019s disease. Our work centres on improving the safety profile of amyloid-targeting treatments while maintaining clinical efficacy.<\/p>\n
We are part of the ICURe Explore programme, working closely with clinicians, researchers, and industry stakeholders to understand real-world adoption, clinical integration, and partnership opportunities.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”2_3,1_3″ custom_padding_last_edited=”on|desktop” _builder_version=”4.27.6″ _module_preset=”default” background_color=”#1A1B4D” custom_margin=”30px||50px||false|false” custom_padding=”40px|40px|40px|40px|true|true” custom_padding_tablet=”30px|30px|30px|30px|true|true” custom_padding_phone=”20px|20px|20px|20px|true|true” border_radii=”on|30px|30px|30px|30px” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.25.2″ _module_preset=”default” background_enable_color=”off” global_colors_info=”{%22gcid-4c79ba3d-a281-4fb6-9b14-02f9a4c793f2%22:%91%22background_color%22%93}”][et_pb_heading title=”Help Shape the Future of Alzheimer\u2019s Treatment” _builder_version=”4.27.6″ _module_preset=”6976b0fd-2a6e-400e-a7ab-854367667fba” title_font=”–et_global_heading_font||||||||” title_text_color=”#FFFFFF” title_font_size=”25px” custom_margin=”||0px||false|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”e7a564bb-6a65-4b14-9846-5d6b684cf4df” text_font=”–et_global_body_font|300|||||||” text_text_color=”#FFFFFF” global_colors_info=”{}”]<\/p>\n
We are gathering insights from clinicians and industry professionals to better understand adoption, safety, and real-world implementation. Your input will help guide the development of safer, more effective Alzheimer\u2019s therapies.<\/p>\n
[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.25.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_button button_url=”https:\/\/research.typeform.com\/to\/Sxuh2BpQ” url_new_window=”on” button_text=”Complete the Survey” button_alignment=”right” button_alignment_tablet=”left” button_alignment_phone=”left” button_alignment_last_edited=”on|tablet” _builder_version=”4.27.6″ _module_preset=”003de22d-416e-481c-86a7-51d2caaf0405″ button_text_size=”13px” button_text_color=”#D4B4F9″ button_border_color=”#D4B4F9″ custom_margin=”30px||||false|false” custom_margin_tablet=”30px||||false|false” custom_margin_phone=”-3px||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”17px|50px|17px|40px|true|false” hover_enabled=”0″ global_colors_info=”{%22gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460%22:%91%22button_text_color%22%93}” sticky_enabled=”0″][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Features & Video” _builder_version=”4.27.6″ _module_preset=”afd460cc-f6d0-4b9d-b4be-304acb0693ae” background_color=”#1A1B4D” custom_margin=”0px||||false|false” custom_padding=”100px||100px||true|false” hover_enabled=”0″ locked=”off” collapsed=”on” global_colors_info=”{%22gcid-1f1bf5fb-a99d-4acc-8d9e-ddac074c158c%22:%91%22background_color_gradient_stops%22%93,%22gcid-a78660e1-cfc7-4771-a566-6834d6a7f06a%22:%91%22background_color_gradient_stops%22%93,%22gcid-24b0db87-dafa-47d9-995f-b90181e18c52%22:%91%22background_color_gradient_stops%22%93}” module_id=”learn” sticky_enabled=”0″][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” gutter_width=”2″ make_equal=”on” _builder_version=”4.27.6″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.25.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Targeted Amyloid Clearance” use_icon=”on” font_icon=”||fa||900″ icon_color=”#1A1B4D” _builder_version=”4.27.6″ _module_preset=”e26e2c24-6c7e-4666-a99d-bf3bfa25798b” header_font=”–et_global_heading_font||||||||” header_text_color=”#1A1B4D” body_font=”–et_global_body_font||||||||” custom_margin=”||30px||false|false” locked=”off” global_colors_info=”{%22gcid-d7cd5a78-aaef-4f36-82a3-4d3706015cba%22:%91%22link_text_color%22,%22link_text_color%22,%22link_text_color%22,%22link_text_color%22,%22link_text_color%22,%22link_text_color%22%93,%22gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460%22:%91%22link_text_color%22,%22quote_text_color%22,%22quote_border_color%22,%22link_text_color%22,%22quote_text_color%22,%22quote_border_color%22,%22link_text_color%22,%22quote_text_color%22,%22quote_border_color%22%93}” quote_font_size_tablet=”20px” quote_font_size_phone=”16px” quote_font_size_last_edited=”on|desktop”]<\/p>\n
We develop engineered antibodies that target and remove disease-causing amyloid from the brain, maintaining the core mechanism of existing therapies.<\/p>\n
[\/et_pb_blurb][et_pb_button button_text=”Connect With Our Team” button_alignment=”center” _builder_version=”4.27.6″ _module_preset=”480fe682-50a9-4927-8d88-261e97d9c305″ button_bg_color=”#D4B4F9″ hover_enabled=”0″ custom_css_main_element=”width: 100%” global_colors_info=”{}” button_bg_color__hover_enabled=”on|hover” button_bg_color__hover=”#1A1B4D” button_bg_enable_color__hover=”on” button_url=”https:\/\/alzorabio.com\/index.php\/contact-page\/” sticky_enabled=”0″][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.6″ _module_preset=”55f1fdbd-df3e-44c0-99ea-f56f922b4607″ background_color=”#D4B4F9″ global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#FFFFFF” icon_width=”50px” align=”left” _builder_version=”4.27.6″ _module_preset=”default” custom_margin=”||30px||false|false” global_colors_info=”{}”][\/et_pb_icon][et_pb_heading title=”Reduced Side Effects” _builder_version=”4.27.6″ _module_preset=”6976b0fd-2a6e-400e-a7ab-854367667fba” title_font=”–et_global_heading_font||||||||” title_text_color=”#FFFFFF” custom_margin=”||10px||false|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”d4bf98c7-0ca4-43df-b91e-5ed3c2635018″ text_font=”–et_global_body_font||||||||” global_colors_info=”{}”]<\/p>\n
Our approach is designed to reduce immune overactivation, lowering the risk of inflammation, microbleeds, and brain swelling associated with current treatments.<\/p>\n
[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.6″ _module_preset=”default” background_image=”https:\/\/alzorabio.com\/wp-content\/uploads\/2025\/11\/Brain-Scans.png” border_radii=”on|30px|30px|30px|30px” global_colors_info=”{}”][et_pb_divider show_divider=”off” _builder_version=”4.25.2″ _module_preset=”default” height_tablet=”50vw” height_phone=”50vw” height_last_edited=”on|phone” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/www.youtube.com\/watch?v=p5oH02zO-RI&t=56s” image_src=”\/\/i.ytimg.com\/vi\/p5oH02zO-RI\/hqdefault.jpg” _builder_version=”4.27.6″ _module_preset=”7044e12c-8309-4651-a22b-c4bc3dc1649b” global_colors_info=”{}”][\/et_pb_video][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Programs” _builder_version=”4.27.6″ _module_preset=”c6252a93-7079-41ad-a1de-374f79e4e1ec” custom_margin=”24px||24px||true|false” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Key Applications & Opportunities” _builder_version=”4.27.6″ _module_preset=”b561d760-fec3-4894-afcb-2b0f9eaee7ed” title_font=”–et_global_heading_font||||||||” global_colors_info=”{}”][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/alzorabio.com\/wp-content\/uploads\/2026\/04\/Patient-Eligibility.png” title_text=”Patient Eligibility” _builder_version=”4.27.6″ _module_preset=”995a9bde-c78f-44f2-8e6b-38f2359efeee” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][et_pb_heading title=”Expanding Patient Eligibility” _builder_version=”4.27.6″ _module_preset=”6976b0fd-2a6e-400e-a7ab-854367667fba” title_font=”–et_global_heading_font||||||||” custom_margin=”||0px||false|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”e7a564bb-6a65-4b14-9846-5d6b684cf4df” text_font=”–et_global_body_font||||||||” text_font_size=”17px” custom_margin=”||10px||false|false” global_colors_info=”{}”]<\/p>\n
Current antibody therapies are limited by safety concerns, restricting treatment to a small proportion of patients. Our approach aims to expand the eligible population through improved safety.<\/p>\n
[\/et_pb_text][et_pb_heading title=”Impact: Up to 3x increase in eligible patients” _builder_version=”4.27.6″ _module_preset=”c8a67fc9-4c23-41fb-9fb6-d0146d1eb229″ title_text_color=”gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460″ global_colors_info=”{%22gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460%22:%91%22title_text_color%22%93}”][\/et_pb_heading][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/alzorabio.com\/wp-content\/uploads\/2026\/04\/Reducing-monitoring-burden.png” title_text=”Reducing monitoring burden” _builder_version=”4.27.6″ _module_preset=”995a9bde-c78f-44f2-8e6b-38f2359efeee” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][et_pb_heading title=”Reducing Monitoring Burden” _builder_version=”4.27.6″ _module_preset=”6976b0fd-2a6e-400e-a7ab-854367667fba” title_font=”–et_global_heading_font||||||||” custom_margin=”||0px||false|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”e7a564bb-6a65-4b14-9846-5d6b684cf4df” text_font=”–et_global_body_font||||||||” text_font_size=”17px” custom_margin=”||10px||false|false” global_colors_info=”{}”]<\/p>\n
Frequent MRI monitoring is a key barrier to adoption. By reducing the risk of ARIA, our approach has the potential to lower the need for intensive imaging and ease pressure on healthcare systems.<\/p>\n
[\/et_pb_text][et_pb_heading title=”Impact: Lower MRI demand & system cost” _builder_version=”4.27.6″ _module_preset=”c8a67fc9-4c23-41fb-9fb6-d0146d1eb229″ title_text_color=”gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460″ locked=”off” global_colors_info=”{%22gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460%22:%91%22title_text_color%22%93}”][\/et_pb_heading][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/alzorabio.com\/wp-content\/uploads\/2026\/04\/Earlier-intervention.png” title_text=”Earlier intervention” _builder_version=”4.27.6″ _module_preset=”995a9bde-c78f-44f2-8e6b-38f2359efeee” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_image][et_pb_heading title=”Enabling Earlier Intervention” _builder_version=”4.27.6″ _module_preset=”6976b0fd-2a6e-400e-a7ab-854367667fba” title_font=”–et_global_heading_font||||||||” custom_margin=”||0px||false|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”e7a564bb-6a65-4b14-9846-5d6b684cf4df” text_font=”–et_global_body_font||||||||” text_font_size=”17px” custom_margin=”||10px||false|false” global_colors_info=”{}”]<\/p>\n
A safer antibody profile could support treatment earlier in disease progression and allow for more effective dosing strategies, improving long-term patient outcomes.<\/p>\n
[\/et_pb_text][et_pb_heading title=”Impact: Improved outcomes & treatment adoption” _builder_version=”4.27.6″ _module_preset=”c8a67fc9-4c23-41fb-9fb6-d0146d1eb229″ title_text_color=”gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460″ locked=”off” global_colors_info=”{%22gcid-1f1b4e15-7cc6-4e13-8154-74d77a956460%22:%91%22title_text_color%22%93}”][\/et_pb_heading][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Call to Action” _builder_version=”4.27.6″ _module_preset=”11146adb-762a-47ad-b42a-e296fc724659″ background_color=”#1A1B4D” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.25.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Get in touch with our team to learn more about our research and explore potential collaboration opportunities.” _builder_version=”4.27.6″ _module_preset=”b561d760-fec3-4894-afcb-2b0f9eaee7ed” title_font=”–et_global_heading_font||||||||” title_text_align=”center” title_text_color=”#FFFFFF” title_font_size=”35px” global_colors_info=”{}”][\/et_pb_heading][et_pb_button button_text=”Contact Our Team” button_alignment=”center” _builder_version=”4.27.6″ _module_preset=”480fe682-50a9-4927-8d88-261e97d9c305″ button_bg_color=”#D4B4F9″ hover_enabled=”0″ global_colors_info=”{}” button_bg_color__hover_enabled=”on|hover” button_bg_color__hover=”#1A1B4D” button_bg_enable_color__hover=”on” button_url=”https:\/\/alzorabio.com\/index.php\/contact-page\/” sticky_enabled=”0″][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Alzora Bio is developing next-generation immunotherapy designed to maintain efficacy while reducing ARIA risk, monitoring burden, and barriers to clinical adoption.Alzora Bio is a research group based at the University of Southampton focused on developing next-generation antibody therapies for Alzheimer\u2019s disease. Our work centres on improving the safety profile of amyloid-targeting treatments while maintaining clinical […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-85894","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/pages\/85894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/comments?post=85894"}],"version-history":[{"count":15,"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/pages\/85894\/revisions"}],"predecessor-version":[{"id":86003,"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/pages\/85894\/revisions\/86003"}],"wp:attachment":[{"href":"https:\/\/alzorabio.com\/index.php\/wp-json\/wp\/v2\/media?parent=85894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}